Alnylam Board OKs Safeguard to Protect Investors Against Abusive Tactics, Including Takeover | GenomeWeb

NEW YORK, July 14 (GenomeWeb News) - The board of directors of Alnylam Pharmaceuticals has approved a rights agreement to ensure that its stockholders receive preferred stock purchase rights in case of certain 'abusive tactics,' the Cambridge, Mass.-based RNAi company said today.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.